Back to Search
Start Over
[IMiDs in hematology].
- Source :
-
Bulletin du cancer [Bull Cancer] 2011 Aug; Vol. 98 (8), pp. 879-87. - Publication Year :
- 2011
-
Abstract
- IMiDs belong to a new pharmalogical class, whose principal therapeutic agents are the thalidomide and the lenalidomide. They have immunomodulatory and antiangiogenic properties, as well as a direct effect on tumor cells. Thalidomide and lenalidomide were first approved for multiple myeloma, and in 5q-myelodysplastic syndrome for lenalidomide. Several studies have shown the efficacy of these drugs in others hematologic malignancies. A third component has been developed, the pomalidomide, which may be more effective in certain indications. Here we present an overview of IMiDs in hematology, including mechanisms of action and known significant side effects.
- Subjects :
- Chronic Disease
Hematologic Neoplasms drug therapy
Humans
Immunologic Factors adverse effects
Lenalidomide
Leukemia, Lymphoid drug therapy
Lymphoma, Non-Hodgkin drug therapy
Multiple Myeloma drug therapy
Primary Myelofibrosis drug therapy
Thalidomide analogs & derivatives
Thalidomide pharmacology
Thalidomide therapeutic use
Waldenstrom Macroglobulinemia drug therapy
Immunologic Factors therapeutic use
Myelodysplastic Syndromes drug therapy
Subjects
Details
- Language :
- French
- ISSN :
- 1769-6917
- Volume :
- 98
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Bulletin du cancer
- Publication Type :
- Academic Journal
- Accession number :
- 21827980
- Full Text :
- https://doi.org/10.1684/bdc.2011.1404